Validation of a personalised medicine tool for Multiple Myeloma that predicts treatment effectiveness in patients

Informazioni relative al progetto

MMpredict

ID dell’accordo di sovvenzione: 701143

DOI 10.3030/701143

Progetto chiuso

Data della firma CE 30 Ottobre 2016

Data di avvio 1 Novembre 2016

Data di completamento 31 Ottobre 2020

Finanziato da

• Horizon 2020 Framework Programme

Costo totale € 3 755 802,50

Contributo UE € 2 949 027,50

Coordinato da

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands

Risultati finali

Websites, patent fillings, videos etc. (1)

Promotional and educational material for stakeholders

Promotional and educational material for stakeholders.

Documents, reports (2)

Scientific articles for peer-reviewed journals

Scientific articles for peer-reviewed journals.

Treatment decision matrix

Pubblicazioni

Peer reviewed articles (2)

Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma

Autori: Erik H. van Beers, Daphne Huigh, Lizanne Bosman, Leonie de Best, Rowan Kuiper, Marieke Spaan, Mark van Duin, Pieter Sonneveld, Belinda Dumee, Martin H. van Vliet
Pubblicato in: The Journal of Molecular Diagnostics, Numero Online ahead of print., 2020, Pagina/e Online ahead of print., ISSN 1525-1578
Editore: American Society for Investigative Pathology
DOI: 10.1016/j.jmoldx.2020.10.010

Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study

Autori: Rowan Kuiper, Annemiek Broijl, Mark van Duin, Martin H. van Vliet, Mark-David Levin, Erik H. van Beers, Bronno Van der Holt, Heleen Visser, Markus Hansson, Annette W.G. van der Velden, Belinda Dumee, Michael Vermeulen, Jasper Koenders, H. Berna Beverloo, Marian Stevens-Kroef, Pieter Sonneveld, Anders Waage, Sonja Zweegman
Pubblicato in: Clinical Lymphoma Myeloma and Leukemia, Numero 19/10, 2019, Pagina/e e10-e11, ISSN 2152-2650
Editore: Elsevier
DOI: 10.1016/j.clml.2019.09.014